Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Stoke Therapeutics (STOK) Total Non-Current Liabilities (2022 - 2025)

Historic Total Non-Current Liabilities for Stoke Therapeutics (STOK) over the last 4 years, with Q3 2025 value amounting to $10.4 million.

  • Stoke Therapeutics' Total Non-Current Liabilities fell 801.52% to $10.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $10.4 million, marking a year-over-year decrease of 801.52%. This contributed to the annual value of $2.5 million for FY2024, which is 9347.17% down from last year.
  • According to the latest figures from Q3 2025, Stoke Therapeutics' Total Non-Current Liabilities is $10.4 million, which was down 801.52% from $10.9 million recorded in Q2 2025.
  • Stoke Therapeutics' Total Non-Current Liabilities' 5-year high stood at $53.1 million during Q1 2022, with a 5-year trough of $2.5 million in Q4 2024.
  • Its 4-year average for Total Non-Current Liabilities is $29.7 million, with a median of $36.4 million in 2023.
  • Per our database at Business Quant, Stoke Therapeutics' Total Non-Current Liabilities crashed by 468.56% in 2023 and then crashed by 9347.17% in 2024.
  • Over the past 4 years, Stoke Therapeutics' Total Non-Current Liabilities (Quarter) stood at $39.8 million in 2022, then decreased by 4.69% to $38.0 million in 2023, then tumbled by 93.47% to $2.5 million in 2024, then surged by 320.98% to $10.4 million in 2025.
  • Its Total Non-Current Liabilities stands at $10.4 million for Q3 2025, versus $10.9 million for Q2 2025 and $12.1 million for Q1 2025.